List of Excipients in Branded Drug INJECTAFER

Injectafer Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Injectafer, the U.S. brand for ferric carboxymaltose injection, uses a deliberately minimal parenteral formulation. Its commercial differentiation comes from the iron-carbohydrate complex, high-dose intravenous administration, dosing convenience, and clinical positioning rather than from a complex excipient system. The strongest excipient opportunities are therefore incremental: improved container compatibility, ready-to-use presentations, dilution flexibility, administration-device integration, and differentiated formulations for outpatient infusion and home-based care.

What is Injectafer and how is it formulated?

Injectafer contains ferric carboxymaltose, an intravenous iron-carbohydrate complex that provides 50 mg of elemental iron per mL. The product is supplied as a sterile, aqueous solution in single-dose vials and prefilled syringes in several presentations, including 100 mg/2 mL, 750 mg/15 mL, and 1,000 mg/20 mL configurations depending on the market presentation. The U.S. prescribing information permits administration by intravenous infusion or slow intravenous push under specified conditions. [1]

The labeled inactive ingredients are limited to:

Component	Function
Water for Injection	Vehicle
Sodium hydroxide	pH adjustment
Hydrochloric acid	pH adjustment

The formulation has no preservative, surfactant, antimicrobial agent, or complex buffering system identified in the U.S. label. This composition reduces excipient-related toxicity and simplifies regulatory control for an intravenously administered iron product. [1]

The commercial product is primarily differentiated by:

• High iron concentration
• Ability to deliver large iron doses in one or two administrations
• Reduced infusion burden compared with lower-dose intravenous iron products
• A stable iron-carbohydrate complex designed to control iron release
• Use across iron-deficiency anemia indications, including chronic kidney disease, heart failure, and other conditions where rapid iron repletion is clinically relevant

What excipients protect Injectafer’s formulation?

The excipient system protects Injectafer through pH control, vehicle purity, and compatibility rather than through a conventional stabilizer package.

Water for Injection

Water for Injection is the continuous phase and must meet compendial requirements for parenteral use. Its quality affects particulate formation, sterility assurance, endotoxin control, osmolality, and long-term product stability. Because ferric carboxymaltose is an iron-containing colloidal complex, control of ionic impurities and manufacturing-water quality is important.

Sodium hydroxide and hydrochloric acid

These materials adjust the formulation to the target pH range. They are not intended to provide substantial buffering capacity. This approach limits the number of formulation variables but places greater importance on:

• Tight pH control
• Control of iron oxidation state
• Control of free iron
• Prevention of aggregation or precipitation
• Container-closure compatibility
• Stability after dilution or transfer to an infusion bag

A low-excipient formulation can be commercially advantageous because it reduces the number of potentially leachable, extractable, allergenic, or immunogenic components. It also reduces the scope of excipient-specific clinical and toxicology work.

Why does Injectafer use few excipients?

Ferric carboxymaltose is itself a functional pharmaceutical complex. The carbohydrate component contributes to the physicochemical behavior of the product, including iron sequestration, colloidal stability, and controlled iron release. The formulation does not need a separate polymeric stabilizer or surfactant package to perform the primary product function.

This creates a different development model from conventional small-molecule injections. The main technical risks are not usually caused by excipient incompatibility alone. They arise from the relationship among:

• Iron concentration
• Carbohydrate molecular structure
• Degree of iron loading
• Free iron content
• Particle-size distribution
• Aggregation state
• pH
• Osmolality
• Container materials
• Manufacturing shear and heat exposure

For this reason, an excipient substitution that appears minor may alter product quality attributes. A change in ionic strength, pH, or interfacial chemistry can affect colloidal behavior and iron release.

What formulation patents protect Injectafer?

The most valuable intellectual property around ferric carboxymaltose generally resides in the iron-carbohydrate complex, manufacturing process, compositional parameters, and quality-control methods rather than in the use of common excipients such as water, hydrochloric acid, or sodium hydroxide.

Relevant patent categories include:

Patent category	Commercial relevance
Iron-carbohydrate complex composition	Defines the chemical or structural relationship between iron and the carbohydrate
Manufacturing process	Protects complex formation, reaction conditions, purification, and control of free iron
Particle or molecular-weight specifications	Can limit competing products that use materially different complex attributes
Pharmaceutical composition	May cover concentration, pH, administration, or formulation ranges
Stability and container systems	May protect storage, dilution, or compatibility conditions
Therapeutic use	May cover dosing regimens or treatment of defined patient populations

The core competitive barrier is likely to be replication of the ferric carboxymaltose complex and its critical quality attributes, not ownership of the basic aqueous excipients.

FDA’s Orange Book identifies approved patents and regulatory exclusivity associated with listed drug products when applicable. Injectafer’s patent position should be assessed using the current Orange Book entry for NDA 203565, associated patent certifications, and any litigation docket involving abbreviated applications. [2] Patent expiration dates cannot be inferred reliably from the label because patent-term adjustment, terminal disclaimers, pediatric extensions, continuations, and regulatory exclusivity can change the effective barrier.

What is the Orange Book status of Injectafer?

Injectafer is approved under NDA 203565. It is a chemical drug product, not a biologic licensed under the Public Health Service Act. Accordingly, competitive entry generally follows an ANDA or, depending on the product and regulatory strategy, a 505(b)(2) pathway rather than a biosimilar application. [1,3]

The practical regulatory issues are significant:

1. An applicant must demonstrate pharmaceutical equivalence and bioequivalence or an otherwise acceptable basis for approval.
2. Complex iron products may require more extensive characterization than conventional aqueous small molecules.
3. Differences in iron-carbohydrate structure, particle characteristics, or release behavior can create regulatory questions.
4. An applicant may need to address listed patents through Paragraph IV certification or a section viii statement.
5. A formulation change that introduces a new excipient may require additional safety and compatibility data.

For Injectafer, the regulatory barrier is therefore more complex than a simple comparison of inactive-ingredient lists.

When does Injectafer lose exclusivity?

Injectafer’s commercial exclusivity depends on several separate dates:

Exclusivity component	Significance
New chemical entity exclusivity	Restricts ANDA approval for the applicable statutory period
Orphan-drug exclusivity, if applicable to a specific indication	Blocks approval for the same disease or condition for the protected period
Pediatric exclusivity	Can add six months to qualifying exclusivity or patent protection
Listed patents	May delay approval or launch after patent certification
Litigation settlement	Can establish an agreed launch date before patent expiry
Regulatory approval of a competing complex iron product	May create practical competition even before broad substitution

The statutory exclusivity date and effective patent barriers should be calculated from FDA records and patent prosecution histories, not from the product launch date alone. Injectafer has been marketed for more than a decade, so current value is likely concentrated in patent estate management, product differentiation, and clinical market expansion rather than original regulatory exclusivity.

Which companies are challenging Injectafer?

The relevant competitor groups are broader than conventional generic manufacturers.

Intravenous iron competitors

Injectafer competes directly with:

• Venofer, iron sucrose
• Feraheme, ferumoxytol
• Monoferric, ferric derisomaltose
• INFeD, iron dextran
• Ferrlecit, sodium ferric gluconate complex in sucrose

These products differ in iron-carbohydrate structure, dose size, administration time, hypersensitivity profile, monitoring requirements, and reimbursement treatment. [4]

Potential complex generic applicants

A competing ferric carboxymaltose product could face several development hurdles:

• Characterizing the carbohydrate component
• Matching iron loading and complex distribution
• Demonstrating comparable stability
• Controlling free or labile iron
• Establishing comparable pharmacodynamic behavior
• Showing acceptable safety for hypersensitivity and hypophosphatemia
• Demonstrating container and dilution compatibility

The product may therefore be vulnerable to a complex generic or 505(b)(2) competitor, but the entry pathway is more technically demanding than for a conventional injectable with a single defined molecular entity.

Biosimilar risk

Injectafer does not face biosimilar risk in the strict legal sense because ferric carboxymaltose is not a therapeutic protein or other biological product regulated through the biosimilar pathway. The more relevant risks are complex generic substitution, 505(b)(2) competition, therapeutic interchange, and branded intravenous iron competition.

What excipient opportunities exist for Injectafer?

The most commercially credible opportunities involve delivery and handling rather than replacing the current pH-adjustment agents.

Ready-to-use presentations

A ready-to-use product can reduce pharmacy compounding, preparation time, and contamination risk. Potential formats include:

• Larger-volume infusion bags
• Pre-diluted presentations
• Ready-to-administer syringes
• Pharmacy bulk packages where permitted
• Unit-dose presentations optimized for outpatient infusion

The value depends on whether the presentation reduces labor and waste without compromising stability or increasing cold-chain requirements.

Container-closure improvements

Container materials can influence adsorption, extractables, leachables, particulate generation, and oxygen exposure. Potential development areas include:

• Polymer containers with lower extractables
• Improved vial coatings
• Enhanced rubber stopper compatibility
• Low-sorption syringe systems
• Light-protective packaging
• Integrated tamper-evident systems

For an iron-containing product, visible and subvisible particulate control is commercially important. A container change that improves particulate performance or reduces handling loss could support a differentiated product or lifecycle-management filing.

Dilution and infusion compatibility

Clinicians and pharmacies value predictable dilution behavior. A formulation or presentation that supports a broader range of infusion fluids, container materials, and hold times could offer practical advantages.

Relevant performance claims could include:

• Longer in-use stability after dilution
• Reduced precipitation risk
• Lower particulate formation
• Greater compatibility with standard infusion bags
• Simplified administration instructions
• Less need for immediate use after preparation

These claims would require robust stability and compatibility data. They also could support hospital formulary adoption even without a new active ingredient.

Preservative-free multidose concepts

A multidose presentation could reduce packaging waste, but it would introduce substantial sterility and antimicrobial-preservation challenges. For intravenous iron, a preservative-free single-dose architecture is likely to remain commercially safer unless a multidose system delivers a clear economic advantage.

Home-infusion and ambulatory formats

The market is moving toward lower-burden infusion models. Excipient and packaging development could support:

• Compact single-use infusion systems
• Prefilled administration devices
• Smaller-volume, higher-concentration formats
• Products stable at room temperature
• Simplified nurse-administered dosing
• Controlled delivery through ambulatory pumps

The commercial opportunity is strongest where the formulation reduces chair time, pharmacy manipulation, and clinical monitoring.

How does Injectafer compare with competing intravenous iron products?

Product	Active iron complex	Typical commercial distinction	Excipient opportunity
Injectafer	Ferric carboxymaltose	High-dose iron replacement, broad use	Ready-to-use delivery, compatibility, container systems
Monoferric	Ferric derisomaltose	High-dose administration	Similar opportunity in convenience and administration
Feraheme	Ferumoxytol	High-dose intravenous iron with distinct safety and imaging considerations	Device, dilution, and handling improvements
Venofer	Iron sucrose	Established use, especially chronic kidney disease	Packaging efficiency and administration convenience
Ferrlecit	Sodium ferric gluconate complex in sucrose	Dialysis-associated use	Dose presentation and pharmacy workflow
INFeD	Iron dextran	High-dose dextran-based replacement	Hypersensitivity management and administration systems

Injectafer’s excipient system is unlikely to create a decisive advantage by itself. The more important comparison is total treatment cost, number of visits, infusion duration, reimbursement, adverse-event management, and institutional workflow.

What manufacturing and IP barriers affect new Injectafer formulations?

Manufacturing is a central barrier because ferric carboxymaltose is a complex material rather than a simple dissolved active ingredient. A competitor must control the product across multiple levels:

• Raw-material variability in the carbohydrate feedstock
• Iron-to-carbohydrate ratio
• Reaction temperature and pH
• Reaction time and mixing
• Purification and residual reagents
• Molecular-weight distribution
• Particle-size distribution
• Free iron and labile iron
• Sterile filtration or aseptic processing
• Final container compatibility

An excipient change can trigger a broader comparability exercise if it changes these attributes. The commercial implication is that a new formulation may require more than routine pharmaceutical-equivalence testing.

Potential IP barriers include process patents, analytical methods, complex composition claims, formulation ranges, and use patents. Manufacturing know-how may also be difficult to reproduce even where formal patent claims are narrow.

What Paragraph IV challenges and litigation risks exist?

A competitor seeking ANDA approval may file a Paragraph IV certification against listed patents, asserting that the patents are invalid, unenforceable, or not infringed. The sponsor of Injectafer could respond with patent litigation, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments. [5]

The most likely dispute topics are:

• Whether the proposed product falls within a complex-composition claim
• Whether process claims apply to the competitor’s manufacturing route
• Whether the proposed product has the claimed iron-carbohydrate characteristics
• Whether method-of-use claims cover the proposed label
• Whether a section viii statement can omit protected uses
• Whether a formulation or container claim is infringed

Settlement agreements could permit an earlier launch than patent expiration. Their economic effect depends on launch timing, royalty terms, authorized-generic arrangements, supply obligations, and restrictions on the competing label.

What commercial opportunities exist beyond excipients?

The largest opportunities are likely to arise from the product’s administration economics.

Hospital and infusion-center contracting

A lower-preparation presentation can reduce pharmacy labor, infusion-chair utilization, and discarded product. Hospitals may value predictable total cost more than a lower acquisition price.

Chronic kidney disease

Injectafer competes in a large intravenous iron market linked to nephrology, dialysis, and renal anemia management. Product differentiation can focus on scheduling, dose completion, and administration workflow.

Heart failure

Intravenous iron products have been studied in heart-failure populations with iron deficiency. A formulation that simplifies outpatient administration could support cardiology and hospital-transition programs. Clinical claims remain dependent on the approved label and supporting evidence. [1,6]

Retail and ambulatory infusion

A convenient presentation may help shift treatment from hospital outpatient departments to ambulatory infusion centers or physician offices. This can expand access while reducing facility costs.

International licensing

Licensing opportunities may include regional commercialization rights, contract manufacturing, device partnerships, and co-development of ready-to-use presentations. Parties with sterile-fill capacity, hospital sales infrastructure, or specialty-pharmacy distribution are logical counterparties.

How strong is the Injectafer excipient strategy?

The excipient strategy is strong for safety simplicity and manufacturing control but limited as a standalone differentiation platform.

Dimension	Assessment
Excipient simplicity	Strong
Parenteral safety profile from inactive ingredients	Favorable
Room for conventional excipient innovation	Limited
Container and delivery opportunity	Moderate to strong
Formulation patent opportunity	Moderate, if tied to measurable performance
Generic substitution barrier	Driven mainly by complex active structure
Biosimilar exposure	Not applicable
Commercial lifecycle-management potential	Strongest in presentation and administration

The most defensible development program would connect any excipient or packaging change to a measurable clinical or economic outcome: shorter preparation time, lower waste, broader dilution compatibility, longer in-use stability, lower particulate burden, or simplified administration.

Key Takeaways

• Injectafer uses a minimal excipient system consisting primarily of Water for Injection and pH-adjustment agents.
• The ferric carboxymaltose complex, not the inactive ingredients, is the main source of product differentiation and technical risk.
• Conventional excipient substitution offers limited commercial upside unless it improves stability, compatibility, handling, or administration.
• Ready-to-use bags, prefilled syringes, improved container systems, and ambulatory-infusion formats are the strongest lifecycle opportunities.
• Injectafer faces complex-generic and 505(b)(2) risk rather than traditional biosimilar risk.
• Patent disputes are more likely to focus on the iron-carbohydrate complex, manufacturing process, composition, and method of use than on water, hydrochloric acid, or sodium hydroxide.
• Commercial value is closely tied to infusion-center economics, dose convenience, reimbursement, and reduced pharmacy workload.

FAQs

Can Injectafer be reformulated with a surfactant?

Technically, a surfactant could be evaluated, but its benefit would need to outweigh new risks involving parenteral tolerability, extractables, aggregation, and regulatory comparability. The current formulation does not identify a surfactant as necessary.

Are Injectafer’s excipients protected by separate patents?

Common excipients such as water, sodium hydroxide, and hydrochloric acid are unlikely to provide meaningful exclusivity by themselves. Protection is more likely to attach to the ferric carboxymaltose composition, manufacturing process, formulation parameters, or delivery system.

Could a prefilled syringe replace the Injectafer vial?

A prefilled syringe could improve preparation efficiency and reduce transfer steps, but development would require assessment of syringe-material compatibility, extractables and leachables, particulate formation, dose accuracy, administration force, and stability.

Is ferric carboxymaltose a biologic requiring a biosimilar pathway?

No. Ferric carboxymaltose is regulated as a drug product rather than as a biologic subject to the biosimilar pathway. Competitive products may pursue ANDA or 505(b)(2) strategies depending on their formulation, characterization, and regulatory design.

What is the most attractive commercial formulation opportunity for Injectafer?

A ready-to-administer presentation with validated room-temperature stability, low particulate generation, broad infusion compatibility, and reduced pharmacy preparation is likely the most attractive opportunity. Its value would come from lower treatment friction and total administration cost rather than from a new therapeutic mechanism.

References

1. U.S. Food and Drug Administration. (2024). Injectafer (ferric carboxymaltose injection) prescribing information. American Regent, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals. https://www.fda.gov/drugs

4. Auerbach, M., & Macdougall, I. C. (2014). Safety of intravenous iron formulations: Facts and folklore. Blood Transfusion, 12(3), 296-300.

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs

6. Ponikowski, P., Kirwan, B. A., Anker, S. D., et al. (2020). Ferric carboxymaltose for iron deficiency at discharge after acute heart failure hospitalization. The Lancet, 396(10266), 1895-1904.